Novo Nordisk launches 7.2 mg Wegovy HD in the US with a $399 self-pay price

Novo Nordisk's higher-dose Wegovy injection became available in the United States in April 2026, according to the company's second-quarter financial report. Wegovy HD is a 7.2 mg single-dose semaglutide pen, and NovoCare Pharmacy lists it at $399 a month for patients who pay out of pocket ^[1][2].

The Q2 2026 report, released August 4, 2026, lists Wegovy HD as approved and launched in the US among the company's commercial highlights for the first half of the year ^[1]. The same report says the 7.2 mg single-dose pen launched in the UK in June, and that a roll-out across the European Union is planned for the second half of 2026 ^[1]. The European Medicines Agency approved the 7.2 mg pen in July, based on STEP UP trial data showing up to 20.7% mean weight loss ^[1]. That 20.7% figure is an average across trial participants, not a result any one patient should expect.

For context on the wider franchise, the report says total Wegovy prescriptions in the US for the week ending July 17 were around 575,000, including more than 265,000 weekly prescriptions for the Wegovy pill, and more than 5 million prescriptions since the pill's launch. Measured by new patient starts, the report says the Wegovy franchise remains the market leader among branded obesity medications in the US ^[1]. Those figures cover the whole Wegovy line, not the 7.2 mg pen specifically.

What the pen costs

NovoCare Pharmacy, Novo Nordisk's direct-to-patient pharmacy, publishes self-pay prices for the Wegovy line ^[2]. Patients new to the Wegovy Savings Offer and NovoCare Pharmacy pay $199 for each month of 0.25 mg and 0.5 mg, and that offer covers two monthly fills through December 31, 2026. After that, the listed self-pay price is $349 a month for Wegovy 0.25 mg, 0.5 mg, 1 mg, 1.7 mg or 2.4 mg, and $399 a month for Wegovy HD (semaglutide) injection 7.2 mg ^[2].

The pharmacy's terms define one month of Wegovy as one box of four pens, note that self-pay pricing varies by dose, and state that Novo Nordisk can modify or cancel the program at any time ^[2]. The same page lists the Wegovy pill starting at $149 a month for self-pay and the Wegovy pen at $199 a month under separate insurance terms ^[2].

Not reported in these materials: whether insurers cover the 7.2 mg pen, what pharmacies other than NovoCare charge for it, or how many patients have been prescribed the higher dose since April.

Why it matters for patients

The 7.2 mg strength adds a step above the 2.4 mg injectable dose that the NovoCare price guide lists for Wegovy ^[2]. For people paying cash, that difference is $50 a month at listed prices, and the $199 introductory price applies only to the 0.25 mg and 0.5 mg strengths, not to 7.2 mg ^[2].

Dose selection is a clinical judgment made with a prescriber, and the company's 20.7% mean weight loss figure comes from trial data and describes an average, not an individual outcome ^[1].

Availability is also uneven by country. The 7.2 mg pen is on the market in the US and the UK, while EU roll-out is planned for the second half of 2026 ^[1].

What happens next

Novo Nordisk says the roll-out of the Wegovy 7.2 mg single-dose pen across the EU is planned in the second half of 2026 ^[1]. The current NovoCare savings terms run through December 31, 2026, after which the listed self-pay prices step up to $349 and $399 a month depending on dose ^[2]. The company raised its 2026 guidance and now expects adjusted sales growth and adjusted operating profit growth of 0% to -6% at constant exchange rates, citing increased expectations for GLP-1 product sales ^[1].